Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | PTAFR | P25105 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665011 | 0.86 | PARP10 (0.46) | CYP11B1SRD5A1PARP10PARP11CYP19A1 | |
| SCHEMBL25501699 | 0.79 | ACHE (0.39) | ACHE | |
| SCHEMBL24727675 | 0.74 | PGR (0.49) | PARP10PARP11ACHE | |
| SCHEMBL19422232 | 0.73 | PARP10 (0.55) | SRD5A1PARP10PARP11CYP19A1CYP11B2 | |
| SCHEMBL10044943 | 0.72 | CA9 (0.42) | ACHE | |
| SCHEMBL13218782 | 0.69 | PARP10 (0.44) | SRD5A1PARP10PARP11CYP19A1CYP11B2 | |
| SCHEMBL20014806 | 0.69 | SLC6A2 (0.43) | SRD5A1ACHE | |
| SCHEMBL803069 | 0.67 | MIF (0.54) | SRD5A1PARP10PARP11ACHE | |
| SCHEMBL23474573 | 0.67 | CYP11B1 (0.39) | CYP11B1SRD5A1CYP19A1CYP11B2NOTUM | |
| SCHEMBL13849161 | 0.66 | CYP11B2 (0.46) | CYP11B1SRD5A1PARP10CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | CYP11B1 1875/4885SRD5A1 2692/4885PARP10 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.